These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18424306)

  • 1. Stopping trials early for benefit: too good to be true.
    Lancet; 2008 Apr; 371(9621):1310. PubMed ID: 18424306
    [No Abstract]   [Full Text] [Related]  

  • 2. [Introduction to randomized trials: the choice of endpoint].
    Simon EG; Fouché CJ; Perrotin F
    Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939
    [No Abstract]   [Full Text] [Related]  

  • 3. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
    Hothorn LA; Wassmer G
    J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 5. Inference for Surrogate Endpoint Validation in the Binary Case.
    Bebu I; Mathew T; Agan B
    J Biopharm Stat; 2015; 25(6):1272-84. PubMed ID: 25616958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the measure of a new drug: is survival the only thing that matters?
    Sargent DJ; Hayes DF
    J Clin Oncol; 2008 Apr; 26(12):1922-3. PubMed ID: 18421044
    [No Abstract]   [Full Text] [Related]  

  • 7. Designing multiregional trials under the discrete random effects model.
    Lan KK; Pinheiro J; Chen F
    J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A reflection on the possibility of finding a good surrogate.
    Alonso A; Meyvisch P; Van der Elst W; Molenberghs G; Verbeke G
    J Biopharm Stat; 2019; 29(3):468-477. PubMed ID: 30686082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating and adjusting for premature censoring of progression-free survival.
    Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
    J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials.
    Brown PM; Rogne T; Solligård E
    Pharm Stat; 2021 Mar; 20(2):413-417. PubMed ID: 32893957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping a trial early - and then what?
    Wittes J
    Clin Trials; 2012 Dec; 9(6):714-20. PubMed ID: 22879573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating surrogate endpoints.
    Hughes MD
    Control Clin Trials; 2002 Dec; 23(6):703-7. PubMed ID: 12505247
    [No Abstract]   [Full Text] [Related]  

  • 13. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 14. A multistage analysis strategy for a clinical trial to assess successively more stringent criteria for a primary endpoint with a low event rate.
    Li S; Hussey MA; Schwartz TA; Koch GG
    Pharm Stat; 2013; 12(2):65-73. PubMed ID: 23424092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment effects and placebo effects.
    Sedgwick P
    BMJ; 2015 Jan; 350():h267. PubMed ID: 25596585
    [No Abstract]   [Full Text] [Related]  

  • 16. A perfect correlate does not a surrogate make.
    Baker SG; Kramer BS
    BMC Med Res Methodol; 2003 Sep; 3():16. PubMed ID: 12962545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical considerations for noninferiority/equivalence trials in vaccine development.
    Wang WW; Mehrotra DV; Chan IS; Heyse JF
    J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical considerations when using a composite endpoint for comparing treatment groups.
    Gómez G; Lagakos SW
    Stat Med; 2013 Feb; 32(5):719-38. PubMed ID: 22855368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.
    Banerjee B; Biswas A
    J Biopharm Stat; 2014; 24(3):649-59. PubMed ID: 24697719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
    Helft G; Beygui F; le Feuvre C; Metzger JP
    Circulation; 2001 Nov; 104(22):E124. PubMed ID: 11723037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.